Mariner
PTCT icon

Mariner’s PTC Therapeutics PTCT Stock Holding History

Mariner’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$901K Buy
11,044
+473
+4% +$34.2K ﹤0.01% 2026
2026
Q1 		$720K Sell
10,571
-1,719
-14% -$122K ﹤0.01% 2215
2025
Q4 		$934K Buy
12,290
+3,545
+41% +$258K ﹤0.01% 1997
2025
Q3 		$537K Buy
8,745
+426
+5% +$22.2K ﹤0.01% 2371
2025
Q2 		$406K Buy
+8,319
New +$395K ﹤0.01% 2495

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Mariner's PTCT Position: Q2 2026 in Review

Mariner increased its PTC Therapeutics (PTCT) stake by 4.5% in Q2 2026, buying an estimated $34.2K and bringing the position to 11,044 shares worth $901K. The position accounts for ﹤0.01% of the portfolio, ranked #2026.

Mariner first reported a position in PTCT in Q2 2025 and has held it in 5 quarters since. The position peaked at $934K in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Mariner held 11,044 shares of PTC Therapeutics worth $901K as of Q2 2026.
  • Mariner bought 473 PTC Therapeutics shares in Q2 2026, an estimated $34.2K.
  • PTC Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2026 holding.
  • Mariner first reported a position in PTC Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Mariner's PTC Therapeutics position peaked at $934K in Q4 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.